IL17A and metabolic dysfunction-associated steatohepatitis: As described in humans, upregulation of the IL-17 axis and an imbalance of the Th17/Tregs ratio were observed in several murine MASH models and linked to adverse outcomes of the disease (131–133, 146, 147, 152, 156).